0.50 / AMA PRA Category 1 CreditTM 0.60 / CE for Nurses 0.50 / CE for Nurse Practitioners (0.42 pharmacology credit)
This activity is provided by Forefront Collaborative.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This 30-minute online activity is focused on advances in treatment of psoriasis, trends in biologic use in psoriasis, treat-to-target recommendations, screening of patients with psoriasis for psoriatic arthritis, and treatment of psoriatic arthritis by disease domain. Participants will listen to the audio-recorded presentation and view the slides. They may extend their learning through use of additional resources that are available to download.
This activity is the prework to the live workshop held in conjunction with Maui Derm NP+PA Summer and Fall 2017 meetings. For more information, please go to www.forefrontcollab.com/mauidermnppa. You may also complete this activity without participating in the live workshop.
The target audience for this educational activity is nurse practitioners and physician assistants who specialize in dermatology. Dermatologists and other clinicians who are members of the healthcare team providing care for patients with psoriasis may benefit from participation in this education.
Upon completion of the activity, participants should be able to:
Identify advances in biologic therapies for moderate to severe plaque psoriasis
Determine the importance of treat-to-target and comparative effectiveness in psoriasis management
Screen psoriasis patients for psoriatic arthritis
There is no fee for this educational activity.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
April Armstrong, MD, MPH Associate Dean for Clinical Research, Associate Professor of Dermatology, Director of Clinical Research, Clinical and Translational Science Institute Director of Clinical Trials and Outcomes Research, Director of Psoriasis Program, Department of Dermatology Keck School of Medicine of USC Los Angeles, CA
Dr. Armstrong has served as a consultant for Novartis, Sanofi, Regeneron, Pfizer, Celgene, Modernizing Medicine, AbbVie, Lilly, Merck, and Janssen; and as a researcher and speaker for Lilly, AbbVie, and Janssen.
Accredited Provider Disclosure
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Miranda Armie and Marianna Shershneva, MD, PhD, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.
The following individuals have disclosed that they and/or their spouse/partner have had a financial relationship in the past 12 months:
Lilia Zurkovsky, PhD, of Forefront Collaborative: salary and stock ownership from Teva Pharmaceuticals
CME Content Review
The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
The Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.60 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.
CE for Nurse Practitioners
This activity is approved for 0.50 contact hours of continuing education, which includes 0.42 hours of pharmacology, by the American Association of Nurse Practitioners. Activity ID 17042646. This activity was planned in accordance with AANP CE Standards and Policies.
Disclosure of Unlabeled Use
This continuing medical education activity does not include reference(s) to unlabeled or unapproved uses of drugs.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.